This decrease closely coincided with the demethylation of the hMLH1 promoter in the tumours, which indicates that peripheral blood can serve as a surrogate tissue for determining pharmacodynamic characteristics of DNMT inhibitors. Here, MLH1 is linked to neoplasm.